Managing QT risk during treatment for blood cancers

Patients with haematologic malignancies may face a distinctive combination of arrhythmic hazards. The malignancy itself can produce anaemia, infection, inflammation, autonomic stress, or metabolic disturbance, while anticancer medicines and supportive treatments may delay ventricular repolarisation. When these influences accumulate, a prolonged corrected QT interval (QTc) can progress to polymorphic ventricular tachycardia, including torsades de pointes, syncope, or sudden cardiac death.

Chemotherapy-induced QT prolongation therefore requires more than a single electrocardiogram (ECG) before treatment. Safe care depends on recognising interacting medicines, correcting potassium and magnesium abnormalities, choosing an appropriate QT correction formula, and establishing a response plan that works across oncology, haematology, cardiology, pharmacy, and emergency services. The principles are especially relevant in Australia, where care may move between large metropolitan centres, regional hospitals, private clinics, and home-based treatment.

Why QT prolongation matters in haematologic malignancy

The QT interval represents ventricular depolarisation and repolarisation. Because it changes with heart rate, clinicians generally assess the QTc rather than the uncorrected interval. Bazett’s formula is familiar but can overcorrect at faster rates and undercorrect at slower rates; Fridericia’s formula may be more reliable when treatment causes tachycardia or bradycardia. Automated ECG measurements should be checked manually when the tracing is abnormal, the T wave is difficult to identify, or the QRS is wide.

A prolonged QTc is a risk marker rather than a diagnosis of torsades. Risk rises with increasing QTc, particularly when the value exceeds 500 milliseconds or increases substantially from baseline, but there is no single threshold that replaces clinical judgement. Bradycardia, pauses, structural heart disease, previous drug-induced QT prolongation, renal or hepatic dysfunction, and a family history of sudden death can all reduce the margin of safety.

Anticancer and supportive medicines that contribute

The medication list should include antineoplastic agents, antiemetics, antimicrobials, analgesics, antidepressants, cardiovascular drugs, complementary products, and medicines obtained without a prescription. Arsenic trioxide is a well-recognised cause of QT prolongation in acute promyelocytic leukaemia. Some tyrosine kinase inhibitors, proteasome inhibitors, immunomodulatory combinations, and other targeted treatments may also affect repolarisation, although risk varies by agent, dose, exposure, and patient characteristics.

Supportive care can add clinically important effects. Ondansetron and other antiemetics, macrolide or fluoroquinolone antibiotics, azole antifungals, methadone, and selected psychotropic medicines may lengthen the QT interval or alter the metabolism of an anticancer drug. Azole-mediated CYP inhibition can increase exposure to medicines cleared through the same pathway. A pharmacist-led interaction review before each cycle is particularly valuable when a patient’s regimen changes rapidly during neutropenic sepsis or an inpatient admission.

Establishing a reliable baseline

Before starting a potentially torsadogenic regimen, obtain an ECG and review symptoms such as palpitations, presyncope, exertional syncope, and unexplained seizures. Document the rhythm, heart rate, QRS duration, QT and QTc values, and the correction method used. A baseline ECG is also useful when later tracings show atrial fibrillation, frequent ectopy, pacing, or bundle branch block, circumstances in which automated QTc interpretation may be unreliable.

Assess kidney and liver function, calcium, potassium, magnesium, nutritional status, and fluid balance. Ask about vomiting, diarrhoea, laxative use, poor intake, alcohol consumption, and non-prescription supplements. Patients treated in Sydney or Melbourne may have direct access to tertiary electrophysiology services, whereas a person in regional Queensland, Western Australia, or the Northern Territory may need a coordinated plan with a local hospital and telehealth support. The baseline assessment should account for that practical difference.

Serial ECG interpretation can become complex after pacing, tachycardia, or changes in ventricular activation. Clinicians may find the discussion of cardiac memory ECG changes useful when separating repolarisation abnormalities from changes caused by altered conduction rather than drug toxicity.

Monitoring through each treatment phase

Monitoring intensity should reflect the medicine, the patient’s risk profile, and the point in the treatment cycle when exposure is expected to peak. For high-risk agents, an ECG before treatment, shortly after initiation or dose escalation, and at steady state is reasonable. Additional testing is warranted after adding an interacting medicine, developing fever or diarrhoea, experiencing a meaningful electrolyte disturbance, or reporting palpitations or faintness.

The ECG should be interpreted alongside symptoms and laboratory results rather than viewed in isolation. A substantial QTc rise from baseline, a QTc above 500 milliseconds, new ventricular ectopy, or a pause-dependent pattern should trigger prompt clinical review. Continuous telemetry is appropriate for selected inpatients receiving high-risk therapy or those with marked prolongation. Outpatient pathways need clear ownership: the treating haematologist should know who reviews an abnormal tracing and who contacts the patient after a critical result.

Electrolytes, interactions, and everyday factors

Maintaining potassium and magnesium in the normal or high-normal range is a central preventive measure, particularly during vomiting, diarrhoea, tumour lysis management, or treatment for infection. Dehydration can worsen renal impairment and increase drug exposure. In Australia’s hot summers, patients may lose fluid through sweating during travel between home, day units, and public transport; advice should balance hydration with cardiac or renal fluid restrictions rather than prescribing a universal volume.

Patients should be told to report fainting, near-fainting, sustained palpitations, or a seizure-like episode immediately. They should not stop anticancer treatment independently, but they should seek urgent advice before taking a newly prescribed antibiotic, antiemetic, or over-the-counter product. Energy drinks, excessive caffeine, stimulant-containing supplements, and recreational drugs can aggravate tachycardia, dehydration, or sleep loss even when they do not directly prolong the QT interval.

Medication reconciliation should include products purchased through Australia’s local pharmacy market, online retailers, and complementary medicine outlets. The Therapeutic Goods Administration (TGA) provides regulatory information, while the Pharmaceutical Benefits Scheme (PBS) affects access and substitution but does not remove the need to check interactions. Pharmacists can help distinguish a permitted generic substitution from a clinically important change in formulation or dose.

Responding when the QTc becomes abnormal

When QTc prolongation is detected, first confirm the measurement and rhythm. Review bradycardia, pauses, pacing, bundle branch block, electrolyte results, renal and hepatic function, and all recent medicines. Correct potassium, magnesium, and calcium abnormalities where appropriate, stop non-essential QT-prolonging drugs, and consider an alternative antiemetic or antimicrobial. A cardiology or electrophysiology opinion is appropriate for marked prolongation, recurrent ventricular ectopy, unexplained syncope, or a history of serious arrhythmia.

For suspected torsades or haemodynamic instability, follow local emergency protocols, provide immediate resuscitation, and use intravenous magnesium when clinically indicated even if the serum magnesium is normal. Correct severe bradycardia or pauses under specialist direction, as pause dependence can sustain the arrhythmia. In Australia, patients and families should know to call 000 for collapse, ongoing chest discomfort, severe breathlessness, or a rapid irregular heartbeat with dizziness rather than attempting to travel to an emergency department unaided.

Treatment decisions should be individualised. A temporary interruption, dose modification, replacement medicine, or monitored rechallenge may preserve cancer control while reducing arrhythmic risk. The decision should be documented with the QTc value, suspected contributors, corrective actions, and the threshold for restarting therapy.

Building a coordinated Australian care pathway

A practical pathway links the haematology unit, cardio-oncology or electrophysiology service, clinical pharmacist, pathology provider, and general practitioner. It should specify which ECG machine or correction method is preferred, how results are communicated, acceptable electrolyte targets, and who authorises treatment changes. This is important when a patient receives chemotherapy in a metropolitan hospital but has blood tests at a community pathology centre or presents to a regional emergency department after hours.

Digital records can support continuity, but documentation should remain clinically usable. Record the date and timing of each ECG in relation to dosing, the complete medication list, laboratory values, symptoms, and the follow-up plan. National and institutional protocols should be checked against current product information and local antimicrobial guidance. Educational material should explain that QT risk is dynamic and can change during an admission, not simply at the start of a cancer regimen.

For clinicians and trainees, themed resources can support continuing education across drug-induced arrhythmia, device management, ablation, and cardio-oncology; the Journal of Arrhythmia article collections provide a useful place to locate related reviews and research. Patient education should remain focused and trustworthy. If broader digital habits arise in a consultation, clinicians can remind patients that commercial pages such as online slot games are entertainment content, not sources of medication or emergency-health advice.

Reducing preventable arrhythmia begins with a consistent process: measure the baseline, review the entire regimen, monitor at clinically meaningful points, correct reversible factors, and respond quickly to warning signs. Australian haematology and cardiology teams can strengthen safety by embedding QT assessment into treatment protocols, pharmacist review, discharge instructions, and communication with regional services. Researchers and clinicians can contribute by reporting real-world drug combinations, ECG outcomes, and practical monitoring models through peer-reviewed arrhythmia and cardio-oncology research.